Brokerages Anticipate Insulet Co. (NASDAQ:PODD) to Post $0.04 Earnings Per Share

Wall Street brokerages predict that Insulet Co. (NASDAQ:PODD) will post earnings per share (EPS) of $0.04 for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Insulet’s earnings, with estimates ranging from ($0.01) to $0.09. Insulet reported earnings of $0.03 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm is scheduled to announce its next earnings report on Thursday, November 7th.

On average, analysts expect that Insulet will report full year earnings of $0.25 per share for the current year, with EPS estimates ranging from $0.17 to $0.39. For the next financial year, analysts forecast that the company will report earnings of $0.85 per share, with EPS estimates ranging from $0.37 to $1.37. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Insulet had a net margin of 2.66% and a return on equity of 7.85%. The business had revenue of $177.10 million during the quarter, compared to the consensus estimate of $163.63 million. During the same quarter in the prior year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 42.5% compared to the same quarter last year.

Several equities research analysts have recently commented on PODD shares. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Jefferies Financial Group boosted their price target on shares of Insulet from $105.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. JPMorgan Chase & Co. upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $120.00 to $155.00 in a report on Tuesday, August 6th. BTIG Research boosted their price target on shares of Insulet to $140.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Finally, BMO Capital Markets boosted their price target on shares of Insulet from $130.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $131.71.

Shares of NASDAQ:PODD traded up $3.67 during trading hours on Friday, hitting $156.26. The company’s stock had a trading volume of 20,854 shares, compared to its average volume of 1,167,662. Insulet has a 52 week low of $70.80 and a 52 week high of $168.00. The company has a debt-to-equity ratio of 2.43, a current ratio of 4.72 and a quick ratio of 3.91. The company has a market capitalization of $8.74 billion, a price-to-earnings ratio of 3,125.20 and a beta of 1.01. The firm’s fifty day moving average price is $147.44 and its 200 day moving average price is $115.61.

In other news, SVP Michael P. Spears sold 4,153 shares of Insulet stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the transaction, the senior vice president now owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shacey Petrovic sold 649 shares of Insulet stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its position in Insulet by 4.9% during the 2nd quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock worth $44,124,000 after purchasing an additional 17,328 shares during the last quarter. Jennison Associates LLC grew its position in Insulet by 53.6% during the 2nd quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock worth $33,882,000 after purchasing an additional 98,995 shares during the last quarter. Swiss National Bank grew its position in Insulet by 2.4% during the 2nd quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock worth $13,168,000 after purchasing an additional 2,600 shares during the last quarter. Columbus Circle Investors grew its position in Insulet by 74.6% during the 2nd quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock worth $19,801,000 after purchasing an additional 70,860 shares during the last quarter. Finally, First Hawaiian Bank grew its position in Insulet by 2,758.3% during the 2nd quarter. First Hawaiian Bank now owns 1,715 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 1,655 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Recommended Story: Depreciation

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit